title: Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs.
abstract: To examine the pharmacokinetic characteristics of sustained-release dexamethasone depots in two separate canine studies.
  
  
  
  Dexamethasone depots loaded with a clinically representative (0.4 mg) dose (DEXTENZA™; Ocular Therapeutix) or an elevated (0.7 mg) dose were inserted into the canaliculi of beagle eyes (n = 37 and n = 34, respectively). Tear fluid was collected for pharmacokinetic analysis of dexamethasone in both studies at predetermined time points. Explanted 0.4 mg depots were collected weekly to measure remaining drug level. Clinical observations and ophthalmic examinations were performed in both studies at each visit.
  
  
  
  The 0.4 mg depots released a median 308 μg by day 15 and tapered to complete drug release by day 28. Median dexamethasone tear fluid concentrations in the 0.4 mg study group decreased from 2,805 ng/mL at day 7 to 0 ng/mL on day 28. Median dexamethasone tear fluid concentrations in the 0.7 mg study group decreased from 4,370 ng/mL at 6 h post insertion to 830 ng/mL on day 35. Mean ± standard deviation intraocular pressures in the 0.4 and 0.7 mg study groups were 20.7 ± 2.8 and 19.0 ± 4.1 mmHg at baseline, respectively, and demonstrated no meaningful change (20.5 ± 3.0 and 20.6 ± 2.9 mmHg, respectively) over the studies' durations. No ocular toxicities were attributed to the dexamethasone depot.
  
  
  
  Sustained-release dexamethasone produced no identifiable ocular toxicity in this animal model, and pharmacokinetics demonstrated a sustained and tapered drug release over 28 days at a 0.4 mg dose and exceeded 35 days at a 0.7 mg dose.
authors.affiliation: Development Group, Ocular Therapeutix , Bedford, Massachusetts.
authors.forename: Charles
authors.initials: C
authors.lastname: Blizzard
authors.affiliation: Development Group, Ocular Therapeutix , Bedford, Massachusetts.
authors.forename: Ankita
authors.initials: A
authors.lastname: Desai
authors.affiliation: Development Group, Ocular Therapeutix , Bedford, Massachusetts.
authors.forename: Arthur
authors.initials: A
authors.lastname: Driscoll
mesh_terms: D060433:Administration, Ophthalmic; D000818:Animals; D003907:Dexamethasone / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D010316:Particle Size; D013666:Tears / Q000378:metabolism*
chemical_list: D009883:Ophthalmic Solutions; D003907:Dexamethasone
keywords: DEXTENZA; dexamethasone; hydrogel; inflammation; pharmacokinetic; sustained release